The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 16672917.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fibrate peroxisome proliferator-activated receptor (PPAR)-alpha ligands are mainly used as hypolipidemic drugs. But this commentary highlights their potential in treating insulin resistance, dyslipidemia, and hypertension and in preventing diabetic nephropathy, inflammation, and cardiovascular disease. Because diabetes is a major contributor to chronic kidney disease and cardiovascular disease, PPAR-alpha agonists may provide greater opportunities for hitting multiple targets in this complex metabolic disease.
Medical subject headings
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Fenofibrate
- Hypolipidemic Agents
- PPAR alpha